Antengene (FRA:722) Total Operating Expense: €36.14 Mil (TTM As of Dec. 2025)


FRA:722 Antengene Corp Ltd FRA:722
39 GF Score
Price €0.43
GF Value €0.16
! 5 Warning Signs
View Full Analysis

What is Antengene Total Operating Expense?

Antengene FRA:722 -7.33% 39 Total Operating Expense is €36.14 Mil as of Dec. 2025. GuruFocus rates FRA:722 with a GF Score™ of 39/100 and a GF Value™ of €0.16. The stock has 5 warning signs investors should review.

Antengene's Total Operating Expense for the six months ended in Dec. 2025 was €19.04 Mil. Antengene's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €36.14 Mil.

Antengene Total Operating Expense Related Terms

Antengene Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Antengene's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene Total Operating Expense Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 85.93 135.47 92.03 55.54 36.21

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.79 31.31 23.47 17.10 19.04
FRA:722
39GF Score
Antengene Corp Ltd FRA:722
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antengene Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €36.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €36.14 Mil mean?
Antengene (FRA:722) has a Total Operating Expense of €36.14 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Antengene and its competitors.
Is Antengene's Total Operating Expense too high?
Antengene's current Total Operating Expense is €36.14 Mil. Overall, Antengene has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Antengene's Total Operating Expense compare to VRTX and REGN?
Antengene's Total Operating Expense of €36.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Antengene and its competitors. Antengene's current Total Operating Expense is €36.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antengene stock overvalued right now?
Antengene (FRA:722) has a current Total Operating Expense of €36.14 Mil. The stock's GF Value™ is €0.16, compared to a current price of €0.43 — trading 168.8% above its estimated fair value. The current Total Operating Expense is €36.14 Mil. Antengene's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Antengene (FRA:722), the current Total Operating Expense is €36.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antengene (FRA:722) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of €0.43 is trading 168.8% above its estimated GF Value™ of €0.16.

Key valuation signals for FRA:722:

  • Total Operating Expense: €36.14 Mil
  • GF Value™: €0.16 vs. price of €0.43 (168.8% above fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antengene Business Description

Other Exchanges 06996:Hong Kong
Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
39GF Score

Get the complete analysis for FRA:722

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.43
Price
€0.16
GF Value